OverviewSuggest Edit

TP Therapeutics is a clinical-stage structure-based drug design company that discovers and develops precision medicines for cancer and other diseases. The company is focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.

TypePublic
Founded2013
HQSan Diego, US
Websitetptherapeutics.com

Latest Updates

Employees (est.) (Mar 2020)102(+18%)
Job Openings1
Share Price (Sept 2020)$78.8 (-2%)
Cybersecurity ratingAMore

Key People/Management at TP Therapeutics

Homa Yeganegi

Homa Yeganegi

Senior Vice President, Project Team Leader and Head of Medical Affairs
Athena M. Countouriotis

Athena M. Countouriotis

President, Chief Executive Officer and Director
Annette North

Annette North

Executive Vice President and General Counsel
Jacob Chacko

Jacob Chacko

Director
Siegfried Reich

Siegfried Reich

Executive Vice President and Chief Scientific Officer
Carol Gallagher

Carol Gallagher

Director
Show more

TP Therapeutics Office Locations

TP Therapeutics has an office in San Diego
San Diego, US (HQ)
10628 Science Center Dr #225
Show all (1)

TP Therapeutics Financials and Metrics

TP Therapeutics Revenue

USD

Net income (Q2, 2020)

(31.5m)

EBIT (Q2, 2020)

(32.7m)

Market capitalization (15-Sept-2020)

3.3b

Closing stock price (15-Sept-2020)

78.8

Cash (30-Jun-2020)

470.5m

EV

2.9b
TP Therapeutics's current market capitalization is $3.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019

General and administrative expense

1.5m4.6m19.8m

R&D expense

15.2m21.1m57.9m

Operating expense total

16.7m25.6m77.7m

EBIT

(16.7m)(25.6m)(77.7m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

3.6m4.7m5.5m39.9m8.6m

R&D expense

10.5m13.7m16.6m22.8m24.2m

Operating expense total

14.1m18.5m22.1m62.6m32.7m

EBIT

(14.1m)(18.5m)(22.1m)(62.6m)(32.7m)
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

45.0m101.0m48.2m

Prepaid Expenses

581.0k494.0k5.8m

Current Assets

45.6m101.5m414.9m

PP&E

256.0k1.0m2.7m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

90.0m78.8m172.4m29.8m470.5m

Prepaid Expenses

1.3m5.0m5.8m8.6m8.4m

Current Assets

91.4m255.2m429.4m389.4m718.9m

PP&E

958.0k954.0k2.2m2.7m2.5m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(16.6m)(24.8m)(72.1m)

Depreciation and Amortization

52.0k138.0k492.0k

Accounts Payable

1.3m(119.0k)903.0k

Cash From Operating Activities

(12.6m)(23.5m)(57.8m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(13.5m)(30.7m)(51.2m)(60.7m)(92.2m)

Depreciation and Amortization

75.0k233.0k322.0k208.0k423.0k

Accounts Payable

1.6m2.6m1.2m(28.0k)(378.0k)

Cash From Operating Activities

(10.2m)(27.1m)(43.7m)(27.9m)(51.2m)
USDFY, 2017

Financial Leverage

1.1 x
Show all financial metrics

TP Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

TP Therapeutics Online and Social Media Presence

Embed Graph

TP Therapeutics Blogs

Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock

SAN DIEGO , May 18, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it has commenced an underwritten public offering, subject to market and other

Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response

Repotrectinib Granted Fast Track Designation in ROS1-Positive Advanced Non-Small Cell Lung Cancer Patients Not Previously Treated with a ROS1 Tyrosine Kinase Inhibitor  First Quarter Progress with Site Activations and Patient Enrollment Across Four Ongoing Clinical Trials including Registrational

Turning Point Therapeutics to Host First Quarter Conference Call

SAN DIEGO , May 04, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report first quarter financial results following the close of U.S.

Turning Point Therapeutics to Host Fourth-Quarter, Full-Year 2019 Conference Call

SAN DIEGO , March 02, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report fourth quarter and 2019 financial results following the close of U.S.

Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific Officer

Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific Officer Content Import Thu, 02/20/2020 - 09:01 Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific Officer Feb 20, 2020 …

Turning Point Therapeutics to Participate in Guggenheim Oncology Day

Turning Point Therapeutics to Participate in Guggenheim Oncology Day Content Import Mon, 02/03/2020 - 09:00 Turning Point Therapeutics to Participate in Guggenheim Oncology Day Feb 03, 2020 This release is a backfill from a News Wire General …
Show more

TP Therapeutics Frequently Asked Questions

  • When was TP Therapeutics founded?

    TP Therapeutics was founded in 2013.

  • Who are TP Therapeutics key executives?

    TP Therapeutics's key executives are Homa Yeganegi, Athena M. Countouriotis and Annette North.

  • How many employees does TP Therapeutics have?

    TP Therapeutics has 102 employees.

  • Who are TP Therapeutics competitors?

    Competitors of TP Therapeutics include Humanetics, NATCO Pharma and Helsinn Group.

  • Where is TP Therapeutics headquarters?

    TP Therapeutics headquarters is located at 10628 Science Center Dr #225, San Diego.

  • Where are TP Therapeutics offices?

    TP Therapeutics has an office in San Diego.

  • How many offices does TP Therapeutics have?

    TP Therapeutics has 1 office.